Screener
Royalty Pharma RPRX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on the most recent quarter.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
FAQ
- What is Royalty Pharma's debt-to-equity?
- Royalty Pharma (RPRX) reported debt-to-equity of 0.9× in Q2 2026.
- How has Royalty Pharma's debt-to-equity changed year-over-year?
- Royalty Pharma's debt-to-equity increased by 8.4% year-over-year, from 0.8× to 0.9×.
- What is the long-term trend for Royalty Pharma's debt-to-equity?
- Over 5 years (2020 to 2025), Royalty Pharma's debt-to-equity has grown at a 9.5% compound annual growth rate (CAGR), from 0.6× to 0.9×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Royalty Pharma's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude